INTERNATIONAL PATENT: IMUNOTERA SOLUÇÕES TERAPÊUTICAS LTDA FILES APPLICATION FOR "HYBRID PROTEIN, HYBRID NUCLEOTIDE SEQUENCE, NUCLEIC ACID MOLECULE, VECTOR FOR HYBRID PROTEIN EXPRESSION, USE OF HYBRID PROTEIN OR NUCLEOTIDE SEQUENCE, FORMULATION, PROCESS FOR PRODUCING A FORMULATION AND METHOD FOR TREATING LESIONS AND/OR CANCER CAUSED BY HUMAN PAPILLOMAVIRUS (HPV) INFECTION"

GENEVA, March 2 -- IMUNOTERA SOLUÇÕES TERAPÊUTICAS LTDA (Av Prof Lineu Prestes, 2242 predio D405508000 São Paulo) filed a patent application (PCT/BR2024/050376) for "HYBRID PROTEIN, HYBRID NUCLEOTIDE SEQUENCE, NUCLEIC ACID MOLECULE, VECTOR FOR HYBRID PROTEIN EXPRESSION, USE OF HYBRID PROTEIN OR NUCLEOTIDE SEQUENCE, FORMULATION, PROCESS FOR PRODUCING A FORMULATION AND METHOD FOR TREATING LESIONS AND/OR CANCER CAUSED BY HUMAN PAPILLOMAVIRUS (HPV) INFECTION" on Aug 22, 2024. With publication no. WO/2025/039059, the details related to the patent application was published on Feb 27, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World In...